Gene · 6139
RPL17: ribosomal protein L17
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPL17: ribosomal protein L17. Genes, record 6139. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6139
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P18621 | Large ribosomal subunit protein uL22 | 184 | 178 | Ensembl, GeneID, HGNC |
Source UniProt
Patents101
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 61992 | P18621 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 61993 | P18621 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 17415 | P18621 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 8803 | P18621 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 17415 | P18621 | Espacenet |
| JP 2025024198 A | 2025-02-19 | 15585 | P18621 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 8803 | P18621 | Espacenet |
| US 12006548 B2 | 2024-06-11 | 483 | P18621 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73963 | P18621 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73965 | P18621 | Espacenet |
1 to 10 of 101
See all 101 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants1,763
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPL17 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 15 | 2025 |
| P30CA047904 | Cancer Center Support Grant | 6 | 2025 |
| P51OD011132 | Emory National Primate Research Center | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 5 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 5 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 5 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 5 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 5 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 4 | 2025 |
1 to 10 of 1,763Source NIH's project files
See all 1,763 nih grantsPapers2,197
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| IGF2BP3 promotes esophageal squamous cell carcinoma progression by regulating global protein translation. | Biochim Biophys Acta Mol Basis Dis | 2027 | 42603622 | PubTator, text mining | PubMed |
| Macrophage Differentiation Selectively Downregulates RPS15A While Preserving RPL13A and RPL17 Expression in THP-1-Derived Macrophages. | J Cardiovasc Dev Dis | 2026 | 42783057 | PubTator, text mining | PubMed |
| Peripheral Th17 Immune Signature Associates with Excellent Response to Anti-PD-1/Anti-PD-L1 Therapy across Solid Tumors. | Cancer Immunol Res | 2026 | 42360819 | PubTator, text mining | PubMed |
| Ventilation-Associated Differences in Lower Airway Microbial Signatures and Peripheral Blood Transcriptome Among Critically Ill COVID-19 Patients. | Infect Drug Resist | 2026 | 42293984 | PubTator, text mining | PubMed |
| Synergistic antitumor and immunomodulatory effects of Bifidobacterium animalis subsp. lactis V9 combined with anti-PD-1 therapy. | Front Immunol | 2026 | 42273689 | PubTator, text mining | PubMed |
| Endothelial cell RpL17-dependent translational control mediates intima-media thickening in response to disturbed flow. | bioRxiv | 2026 | 42244526 | PubTator, text mining | PubMed |
| TB risk during treatment with biological agents and Janus kinase inhibitors: an umbrella review. | Int J Tuberc Lung Dis | 2026 | 42226371 | PubTator, text mining | PubMed |
| Targeting IL-17 family cytokines and receptors in hepatocellular carcinoma: From biology to combination immunotherapy. | Biochim Biophys Acta Rev Cancer | 2026 | 42214769 | PubTator, text mining | PubMed |
| ZDHHC17-Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance. | Adv Sci (Weinh) | 2026 | 42133178 | PubTator, text mining | PubMed |
| Demethylase ALKBH4 Inhibits Cell Proliferation via Induction of 5'-tsRNAGlu in Non-Small Cell Lung Cancer. | Front Biosci (Landmark Ed) | 2026 | 42052838 | PubTator, text mining | PubMed |
1 to 10 of 2,197
See all 2,197 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6139
GET https://conductscience.org/api/genes/v1/6139/patents?page=2